<div class="qMYqUG_convSearchResultHighlightRoot">
<div class="" data-turn-id-container="request-WEB:74b3982d-636b-41f8-a7f7-75919c1a6292-9" data-is-intersecting="true">
<section class="text-token-text-primary w-full focus:outline-none has-data-writing-block:pointer-events-none [&amp;:has([data-writing-block])&gt;*]:pointer-events-auto R6Vx5W_threadScrollVars scroll-mb-[calc(var(--scroll-root-safe-area-inset-bottom,0px)+var(--thread-response-height))] scroll-mt-[calc(var(--header-height)+min(200px,max(70px,20svh)))]" dir="auto" data-turn-id="request-WEB:74b3982d-636b-41f8-a7f7-75919c1a6292-9" data-turn-id-container="request-WEB:74b3982d-636b-41f8-a7f7-75919c1a6292-9" data-testid="conversation-turn-16" data-scroll-anchor="false" data-turn="assistant">
<div class="text-base my-auto mx-auto pb-10 [--thread-content-margin:var(--thread-content-margin-xs,calc(var(--spacing)*4))] @w-sm/main:[--thread-content-margin:var(--thread-content-margin-sm,calc(var(--spacing)*6))] @w-lg/main:[--thread-content-margin:var(--thread-content-margin-lg,calc(var(--spacing)*16))] px-(--thread-content-margin)">
<div class="[--thread-content-max-width:40rem] @w-lg/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1 group/turn-messages focus-visible:outline-hidden relative flex w-full min-w-0 flex-col agent-turn">
<div class="flex max-w-full flex-col gap-4 grow">
<div class="min-h-8 text-message relative flex w-full flex-col items-end gap-2 text-start break-words whitespace-normal outline-none keyboard-focused:focus-ring [.text-message+&amp;]:mt-1" dir="auto" tabindex="0" data-message-author-role="assistant" data-message-id="c276190a-3c8e-4f3c-8094-13ac5555f83b" data-message-model-slug="gpt-5-5" data-turn-start-message="true">
<div class="flex w-full flex-col gap-1 empty:hidden">
<div class="markdown prose dark:prose-invert wrap-break-word w-full light markdown-new-styling">
<h2 data-section-id="k1g9v4" data-start="0" data-end="53"><strong>Tenosynovial Giant Cell Tumors Market Insights</strong></h2>
<p data-start="55" data-end="705">The <a href="https://www.delveinsight.com/report-store/tenosynovial-giant-cell-tumors-tsgcts-market-size"><strong>Tenosynovial Giant Cell Tumors (TGCT) market</strong></a> is witnessing strong growth due to increasing awareness, improved diagnostic capabilities, and the emergence of targeted CSF1R inhibitor therapies. In 2025, the TGCT market across the 7MM was valued at approximately USD 326 million and is projected to grow at a CAGR of 20.8% during 2026&ndash;2036. The United States dominated the market, accounting for nearly 74% of the total revenue share in 2025. The approvals of TURALIO and ROMVIMZA have significantly strengthened the targeted treatment landscape, while upcoming therapies with improved safety profiles are expected to drive future market expansion.</p>
<h3 data-start="707" data-end="732"><strong data-start="707" data-end="732">Key Market Highlights</strong></h3>
<ul data-start="733" data-end="1004">
<li data-section-id="1xjd6o2" data-start="733" data-end="777">CAGR of 20.8% projected during 2026&ndash;2036</li>
<li data-section-id="1abl5q1" data-start="778" data-end="829">7MM market size reached USD 326 million in 2025</li>
<li data-section-id="1086c38" data-start="830" data-end="890">US accounted for approximately 74% of total market share</li>
<li data-section-id="1q9j470" data-start="891" data-end="953">CSF1R inhibitors transforming the TGCT treatment landscape</li>
<li data-section-id="16r9set" data-start="954" data-end="1004">Rising adoption of targeted systemic therapies</li>
</ul>
<h2 data-section-id="1gnopks" data-start="1011" data-end="1070"><strong>Tenosynovial Giant Cell Tumors Epidemiology Insights</strong></h2>
<p data-start="1072" data-end="1736">Tenosynovial Giant Cell Tumors are rare, locally aggressive neoplasms that primarily affect joints, tendon sheaths, and bursae. In 2025, total prevalent cases across the 7MM were estimated at approximately 500,000. The United States accounted for nearly 43% of total cases, followed closely by EU4 and the UK at 42%, while Japan represented around 13% of disease prevalence. Increased disease awareness and advancements in imaging technologies such as <a href="https://www.delveinsight.com/report-store/magnetic-resonance-imaging-devices-market"><strong>MRI</strong></a> are contributing to improved diagnosis and identification of patients eligible for systemic therapies. Both localized and diffuse TGCT forms continue to contribute substantially to the overall disease burden.</p>
<h3 data-start="1738" data-end="1769"><strong>Key Epidemiology Highlights</strong></h3>
<ul data-start="1770" data-end="2071">
<li data-section-id="3yot1f" data-start="1770" data-end="1832">Total prevalent TGCT cases in the 7MM reached 500K in 2025</li>
<li data-section-id="1hyg955" data-start="1833" data-end="1894">US contributed approximately 43% of total prevalent cases</li>
<li data-section-id="1jyd8m9" data-start="1895" data-end="1960">EU4 and the UK accounted for nearly 42% of disease prevalence</li>
<li data-section-id="1hab4zt" data-start="1961" data-end="2008">Japan represented around 13% of total cases</li>
<li data-section-id="1v98z18" data-start="2009" data-end="2071">Improved imaging technologies supporting earlier diagnosis</li>
</ul>
<h2 data-section-id="qwe72v" data-start="2078" data-end="2147">Tenosynovial Giant Cell Tumors Pipeline and Emerging Therapies</h2>
<p data-start="2149" data-end="2825">The <strong><a href="https://www.delveinsight.com/report-store/tenosynovial-giant-cell-tumors-tsgcts-pipeline-insight">TGCT pipeline</a></strong> is rapidly advancing with growing emphasis on CSF1R-targeted therapies aimed at reducing macrophage-mediated tumor growth and inflammation. Emerging therapies are being developed to improve efficacy, reduce recurrence risk, and overcome safety limitations associated with currently available agents. Companies are actively exploring oral, intravenous, and intra-articular treatment approaches to provide more flexible and effective disease management options. Pimicotinib remains one of the most promising late-stage candidates and is expected to significantly strengthen the future TGCT treatment landscape following potential approval in the United States.</p>
<h3 data-start="2827" data-end="2849"><strong data-start="2827" data-end="2849">Key Pipeline Drugs</strong></h3>
<ul data-start="2850" data-end="3092">
<li data-section-id="1debajs" data-start="2850" data-end="2933"><strong data-start="2852" data-end="2867">Pimicotinib</strong> &mdash; Abbisko Therapeutics
<ul data-start="2895" data-end="2933">
<li data-section-id="1w5oafe" data-start="2895" data-end="2933">Macrophage CSF1R antagonist | Oral</li>
</ul>
</li>
<li data-section-id="1rt4qqk" data-start="2935" data-end="3011"><strong data-start="2937" data-end="2952">Emactuzumab</strong> &mdash; SynOx Therapeutics
<ul data-start="2978" data-end="3011">
<li data-section-id="qe7w8h" data-start="2978" data-end="3011">CSF1R inhibitor | Intravenous</li>
</ul>
</li>
<li data-section-id="28gi9x" data-start="3013" data-end="3092"><strong data-start="3015" data-end="3026">AMB 051</strong> &mdash; AmMax Bio
<ul data-start="3043" data-end="3092">
<li data-section-id="ub1skw" data-start="3043" data-end="3092">Macrophage CSF1R antagonist | Intra-articular</li>
</ul>
</li>
</ul>
<h3 data-start="3094" data-end="3117"><strong data-start="3094" data-end="3117">Pipeline Highlights</strong></h3>
<ul data-start="3118" data-end="3424" data-is-last-node="" data-is-only-node="">
<li data-section-id="twuwgk" data-start="3118" data-end="3176">Growing focus on CSF1R-targeted therapeutic approaches</li>
<li data-section-id="1esdaxd" data-start="3177" data-end="3235">Emerging therapies aiming for improved safety profiles</li>
<li data-section-id="11xclk3" data-start="3236" data-end="3302">Multiple administration routes expanding treatment flexibility</li>
<li data-section-id="mipod4" data-start="3303" data-end="3363">Pimicotinib expected to become a major future competitor</li>
<li data-section-id="wigt85" data-start="3364" data-end="3424" data-is-last-node="">Increasing innovation supporting long-term TGCT management</li>
</ul>
</div>
</div>
</div>
</div>
<div class="mt-3 w-full empty:hidden">&nbsp;</div>
</div>
</div>
</section>
</div>
</div>

Tenosynovial Giant Cell Tumor Market

Tenosynovial Giant Cell Tumor Market Infographics

Tenosynovial Giant Cell Tumor Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape